Related references
Note: Only part of the references are listed.The roles of signaling pathways in liver repair and regeneration
Amir Valizadeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases
Thomas Litman
APMIS (2019)
Dysregulated microRNAs in colorectal carcinogenesis: New insight to cell survival and apoptosis regulation
Alireza Anvarnia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Epigenetic changes in gastric cancer induction by Helicobacter pylori
Bahman Yousefi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
MiRNAs and inflammatory bowel disease: An interesting new story
Soheila Moein et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
New insights into the roles and regulation of SphK2 as a therapeutic target in cancer chemoresistance
Leili Hasanifard et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
What is genomic medicine?
Stephanie Clare Roth
JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION (2019)
Modulating tumor hypoxia by nanomedicine for effective cancer therapy
Rana Jahanban-Esfahlan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Candidate biomarkers for Parkinson's disease
Ali Khodadadian et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer
Ying Xu et al.
EXPERIMENTAL CELL RESEARCH (2018)
Recent Progress in Gene Therapy for Ovarian Cancer
Angela Ayen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Molecular mechanisms of drug resistance in ovarian cancer
Leyla Norouzi-Barough et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer
Miran Rada et al.
ONCOGENE (2018)
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Yinghua Zhu et al.
NATURE COMMUNICATIONS (2018)
Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
H. M. Adnan Hameed et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Microorganisms in the Treatment of Cancer: Advantages and Limitations
Klaudia Lukasiewicz et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Cystic fibrosis: a clinical view
Carlo Castellani et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine
M. Zaiou et al.
CLINICAL GENETICS (2017)
Low-, high-coverage, and two-stage DNA sequencing in the design of the genetic association study
Chao Xu et al.
GENETIC EPIDEMIOLOGY (2017)
The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders
Derek K. Smith et al.
PROGRESS IN NEUROBIOLOGY (2017)
Transcriptomics technologies
Rohan Lowe et al.
PLOS COMPUTATIONAL BIOLOGY (2017)
Myopenia and precision (P4) medicine
John E. Morley et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Personalized or Precision Medicine? The Example of Cystic Fibrosis
Fernando A. L. Marson et al.
FRONTIERS IN PHARMACOLOGY (2017)
Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
Henry R. Kranzler et al.
ADDICTION (2017)
RNA mis-splicing in disease
Marina M. Scotti et al.
NATURE REVIEWS GENETICS (2016)
Positional proteomics in the era of the human proteome project on the doorstep of precision medicine
Ulrich Eckhard et al.
BIOCHIMIE (2016)
Genome: Origins and evolution of the term
A. V. Zelenin et al.
MOLECULAR BIOLOGY (2016)
Precision Medicine: What Challenges Are We Facing?
Yu Xue et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2016)
Personalized Proteomics: The Future of Precision Medicine
Trevor T. Duarte et al.
PROTEOMES (2016)
G551D-CFTR needs more bound actin than wild-type CFTR to maintain its presence in plasma membranes
Pascal Trouve et al.
CELL BIOLOGY INTERNATIONAL (2015)
Promising Targets for the Treatment of Neurodegenerative Diseases
S. L. Budd Haeberlein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A New Initiative on Precision Medicine
Francis S. Collins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Precision Medicine-Personalized, Problematic, and Promising
J. Larry Jameson et al.
OBSTETRICAL & GYNECOLOGICAL SURVEY (2015)
Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study
Ken-ei Sada et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
Jennifer E. Miller et al.
BMJ OPEN (2015)
Targeted therapies to improve CFTR function in cystic fibrosis
Malcolm Brodlie et al.
GENOME MEDICINE (2015)
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Steven M. Rowe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael P. Boyle et al.
LANCET RESPIRATORY MEDICINE (2014)
Molecular and Cellular Heterogeneity in Breast Cancer Challenges for Personalized Medicine
Ashley G. Rivenbark et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Database tools in genetic diseases research
Anna Monica Bianco et al.
GENOMICS (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
CFTR mutation analysis and haplotype associations in CF patients
S. K. Cordovado et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Preparing for Precision Medicine
Reza Mirnezami et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A public resource facilitating clinical use of genomes
Madeleine P. Ball et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Badomics words and the power and peril of the ome-meme
Jonathan A. Eisen
GIGASCIENCE (2012)
The cost of drug development: A systematic review
Steve Morgan et al.
HEALTH POLICY (2011)
Mutation Nomenclature in Practice: Findings and Recommendations from the Cystic Fibrosis External Quality Assessment Scheme
Sarah Berwouts et al.
HUMAN MUTATION (2011)
Cancer genomics: from discovery science to personalized medicine
Lynda Chin et al.
NATURE MEDICINE (2011)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Fragmented Gene
Juergen Brosius
NATURAL GENETIC ENGINEERING AND NATURAL GENOME EDITING (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing
Qun Pan et al.
NATURE GENETICS (2008)
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
Mark I. McCarthy et al.
NATURE REVIEWS GENETICS (2008)
Non-coding RNA
JS Mattick et al.
HUMAN MOLECULAR GENETICS (2006)
A haplotype map of the human genome
D Altshuler et al.
NATURE (2005)
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
M Wilschanski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells
CA Sherman-Baust et al.
CANCER CELL (2003)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
P Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Blood donors and factors impacting the blood donation decision
TW Gillespie et al.
TRANSFUSION MEDICINE REVIEWS (2002)
Platelet-active drugs - The relationships among dose, effectiveness, and side effects
C Patrono et al.
CHEST (2001)
Share Paper
